In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015

International Journal of Antimicrobial Agents

Volumn 53, Issue 4, 2019, Pages 456-466

  Karlowsky, James A ^a,b   Hackel, Meredith A ^a   Tsuji, Masakatsu ^c   Yamano, Yoshinori ^c   Echols, Roger ^d   Sahm, Daniel F ^a  

^a International Health Management Associates   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c SHIONOGI AND CO LTD   (Japan)

^d Clinical Development and Medical Affairs LLC   (United States)

Author keywords

Cefiderocol; global; Gram negative bacilli; in vitro; siderophore; surveillance

Indexed keywords

AVIBACTAM; CATION; CEFEPIME; CEFIDEROCOL; CEFTAZIDIME; CEFTOLOZANE; CIPROFLOXACIN; COLISTIN; MEROPENEM; SIDEROPHORE; TAZOBACTAM; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER PITII; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; BURKHOLDERIA CEPACIA COMPLEX; CARBAPENEM RESISTANCE; CITROBACTER FREUNDII; CITROBACTER KOSERI; CLINICAL LABORATORY; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; ENTEROBACTERIACEAE; EUROPE; GRAM NEGATIVE BACTERIUM; HUMAN; IN VITRO STUDY; IRON DEPLETION; MIC50; MIC90; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; BURKHOLDERIA CEPACIA; DRUG EFFECT; GRAM NEGATIVE INFECTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; BURKHOLDERIA CEPACIA; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; PSEUDOMONAS AERUGINOSA; SIDEROPHORES; STENOTROPHOMONAS MALTOPHILIA;

EID: 85062396173     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2018.11.007     Document Type: Article

References (37)

1. KPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob Agents Chemother 60 (2016), 4490–4500.
2. de Jonge, B.L.M., Karlowsky, J.A., Kazmierczak, K.M., Biedenbach, D.J., Sahm, D.F., Nichols, W.W., In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother 60 (2016), 3163–3169.
3. Labarca, J.A., Costa Sallas, M.J., Seas, C., Guzmàn-Blanco, M., Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America. Crit Rev Microbiol 40 (2014), 276–292.
4. Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E. Jr, Gilbert, D., Rice, L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Society of America. Clin Infect Dis 48 (2009), 1–12.
5. World Health Organization. Antimicrobial resistance global report on surveillance. http://www.who.int/drugresistance/documents/surveillancereport/en/, 2014.
6. Vasoo, S., Cunningham, S.A., Cole, N.C., Kohner, P.C., Menon, S.R., Krause, K.M., et al. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing gram-negative bacilli. Antimicrob Agents Chemother 59 (2015), 7842–7846.
7. IMP-6 -carrying Enterobacteriaceae to various antimicrobials, including the siderophore cephalosporin cefiderocol. Antimicrob Agents Chemother, 61, 2017 e00576-17.
8. Castanheira, M., Huband, M.D., Mendes, R.E., Flamm, R.K., Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother, 61, 2017 e00567-17.
9. Dobias, J., Dénervaud-Tendon, V., Poirel, L., Nordmann, P., Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis 36 (2017), 2319–2327.
10. World Health Organization. 2017. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. WHO/EMP/IAU/2017.12.
11. ClinicalTrials.gov. A study of efficacy/safety of intravenous S-649266 versus imipenem/cilastatin in complicated urinary tract infections. Identifier: NTC02321800. https://clinicaltrials.gov/. Accessed 3 January 2018.
12. ClinicalTrials.gov. Study of S-649266 or best available therapy for the treatment of severe infections caused by carbapenem-resistant Gram-negative pathogens. Identifier: NTC02321800. https://clinicaltrials.gov/. Accessed 3 January 2018.
13. ClinicalTrials.gov. Clinical study of S-649266 for the treatment of nosocomial pneumonia caused by Gram-negative pathogens. Identifier: NCT03032380. https://clinicaltrials.gov/. Accessed 3 January 2018.
14. Katsube, T., Wajima, T., Ishibashi, T., Arjona Ferreira, J.C., Echols, R., Pharmacokinetic/pharmacodynamics modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother, 61, 2016 pii:e01381-16.
15. Kawaguchi, N., Katsube, T., Echols, R., Wajima, T., Population pharmacokinetic analysis of cefiderocol, a parenteral cephalosporin, in healthy subjects, subjects with varying renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis. Antimicrob Agents Chemother, 2017 pii: AAC.01391-17.
16. Ghazi, I., Monogue, M.L., Tsuji, M., Nicolau, D.P., Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, explored in a Pseudomonas aeruginosa neutropenic murine thigh model. Int J Antimicrob Agents, 2017 Pii: S0924-8579(17)30372-2.
17. Matsumoto, S., Singley, C.M., Hoover, J., Nakamura, R., Echols, R., Rittenhouse, S., et al. Efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. Antimicrob Agents Chemother 61 (2017), e00700–e00717.
18. Monogue, M.L., Tsuji, M., Yamano, Y., Echols, R., Nicolau, D.P., Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother, 61, 2017 e01022-17.
19. Tsuji, M., Horiyama, T., Toba, S., Nakamura, R., Yamano, Y., S-649266, a novel siderophore cephalosporin: in vivo efficacy in murine infection model caused by multidrug-resistant Gram-negative bacteria, abstr ECCMID-0253. Abstr 25th European Congress of Clinical Microbiology and Infectious Diseases, 2015.
20. Nakamura, R., Toba, S., Tsuji, M., Yamano, Y., Shimada, J., S-649266, a novel siderophore cephalosporin: IV. In vivo efficacy in various murine infection models, abstr F-1558. Abstr 54th Intersci Conf Antimicrob Agents Chemother, 2014.
21. Ito, A., Nishikawa, T., Masumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 60 (2016), 7396–7401.
22. Ito, A., Nishikawa, T., Oota, M., Kanazawa, S., Fukuhara, N., Yamaguchi, T., et al. S\649266, a novel siderophore cephalosporin: Binding affinity to PBP and bactericidal activity, abstr ECCMID-1871. Abstr 25th European Congress of Clinical Microbiology and Infectious Diseases, 2015.
23. Ito, A., Sato, T., Ota, M., Takemura, M., Nishikawa, T., Toba, S., et al. In vitro antibacterial properties of cefiderocol, a novel siderophore, against Gram-negative bacteria. Antimicrob Agents Chemother, 2017, 10.1028/AAC.01454-17.
24. Kohira, N., West, J., Ito, A., Ito-Horiyama, T., Nakamura, R., Sato, T., et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60 (2016), 729–734.
25. Ito-Horiyama, T., Ishii, Y., Ito, A., Sato, T., Nakamura, R., Fukuhara, N., et al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 60 (2016), 4384–4386.
26. Tsuji, M., Kazmierczak, K.M., Hackel, M., Echols, R., Yamano, Y., Sahm, D.F., Cefiderocol (S-649266) susceptibility against globally isolated meropenem nonsusceptible Gram-negative bacteria containing serine and metallo-carbapenemase genes, abstr Sunday-25. Abstr Microbe, 2017.
27. Tsuji, M., Ito, A., Nakamura, R., Yamano, Y., Shimada, J., S-649266, a novel siderophore cephalosporin: in vitro activity against Gram-negative bacteria. Open Forum Infect Dis, 1(Suppl 1), 2014, S108.
28. Hackel, M.A., Tsuji, M., Yamano, Y., Echols, R., Karlowsky, J.A., Sahm, D.F., In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study). Antimicrob Agents Chemother, 61, 2017 e00093-17.
29. Hackel, M.A., Tsuji, M., Yamano, Y., Echols, R., Karlowsky, J.A., Sahm, D.F., In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014-2016. Antimicrob Agents Chemother, 2017, 10.1128/AAC.01968-17.
30. Ito, A., Kohira, N., Nakamura, R., Tsuji, M., Kreiswirth, B., Yamano, Y., S-649266, a novel siderophore cephalosporin: In vitro activity against Gram-negative bacteria including carbapenem resistant strains, abstr ECCMID-0252. Abstr 25th European Congress of Clinical Microbiology and Infectious Diseases, 2015.
31. Falagas, M.E., Skalidis, T., Vardakas, K.Z., Legakis, N.J., Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother 72 (2017), 1704–1708.
32. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Eleventh Edition, 2018, CLSIWayne, PA, USA Approved Standard M07-A11.
33. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 28th edition, 2018, CLSI, Wayne, PA, USA M100.
34. Clinical and Laboratory Standards Institute. Antimicrobial Susceptibility Testing Meeting Minutes and Presentations, January 2016, (clsi.org/standards/micro/microbiology-files), 2016.
35. Tsuji, M., Hackel, M., Echols, R., Sahm, D., Yamano, Y., MIC reproducibility of iron depleted cation adjusted-Mueller Hinton broth (ID-CAMHB) for microdilution testing of S-649266, a novel siderophore cephalosporin, abstr Microbe-M-470. Abstr 1st Microbe, 2016.
36. Otto, B.R., Verweij-van Vught, A.M.J.J., MacLaren, D.M., Transferrins and heme-compounds as iron sources for pathogenic bacteria. Crit Rev Microbiol 18 (1992), 217–233.
37. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 8.0 (valid from 2018-01-01). http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_8.0_Breakpoint_table.pdf, 2018. (Accessed 3 January 2018)